CARA Cara Therapeutics Inc: Market Value to Book Value Ratio
Cara Therapeutics, Inc. (CARA) operates on a virtual drug development model, utilizing external CMO facilities for synthesis. This GURU.Markets terminal chart provides data on the market capitalization to net assets ratio, with the metric currently at 0.90. Growth is driven by the loyalty of nephrology centers, while human capital is sustained through an option system for research chemists.
Cara Therapeutics Inc. (CARA) - metric breakdowns and financial figures
- share price and expert price forecast:
- company stock capitalization data:
- book capitalization data:
- debt and solvency information:
Debt to Equity Cara Therapeutics, Inc.|CARA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Cara Therapeutics, Inc|CARA - Company Cumulative Debt|Debts to Book Capitalization Cara Therapeutics, Inc|CARA - Company Long-Term Liabilities|Company Short-Term Debts Cara Therapeutics|Quick Liquidity caratherapeutics.com
- earnings and valuation multiples indicators:
Comprehensive company analysis:Cara Therapeutics, Inc. - CARA
The P/BV ratio compares the issuer's market value to its net assets, determining the premium or discount to equity. By analyzing the historical P/BV level, an investor assesses asset quality and the risk of impairment. For Cara Therapeutics, Inc. (CARA), the decline in this metric reflects a loss of commercial potential due to failures in clinical trials. Eroding confidence in the platform is destroying the company's economic moat, signaling a high probability of prolonged stagnation.
Main competitors
BIIB: Market Capitalization to Book Value Ratio|neurocrine.com (NBIX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited|Capitalization to Book Value Ratio AXSM (Axsome)|Market Capitalization to Book Value Ratio ACAD|XENE - Market-to-Book Ratio|Viking Therapeutics - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio supernus.com SUPN|CPRX - Market Value to Book Value Ratio|Market Value to Book Value DNLI (Denali)|Harmony Pharma (HRMY) - Market Value to Book Value Ratio|Market-to-Book Ratio Biohaven Corp (BHVN)|AMLX (Amylyx Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio trevitherapeutics.com (TRVI)|Market Capitalization to Book Value Ratio PRAX|Market Capitalization to Book Value Ratio Anavex (AVXL)|Market Value to Book Value Ratio CeriBell Corp CBLL|Market Value to Book Value PRTA|Alector Therapeutics - Market Capitalization to Book Value Ratio|ANNX - Market Capitalization to Book Value Ratio|OMER (omeros.com) - Market Cap to Net Assets Ratio|Neurogene Inc - Market Value to Book Value|Market Cap to Net Assets Ratio ACIU|VYGR (Voyager Corp) - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio NMRA|SCLX (scilexholding.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio TVGN (Tevogen Bio)|Alpha Cognition Inc (ACOG) - Market-to-Book Ratio|CGTX - Market Value to Book Value Ratio|Market Value to Book Value IKT (Inhibikase Pharma)|SAVA: Market Capitalization to Book Value Ratio|Assertio (ASRT) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Coya Therapeutics Inc|VistaGen Therapeutics Inc - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio OVID|ABOS - Market-to-Book Ratio|CervoMed Inc. - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Alterity Therapeutics Ltd. ATHE|CLNN: Market Cap to Net Assets Ratio|PepGen Inc. - Market Cap to Book Value Multiple|JUNS: Market Capitalization to Book Value Ratio|RLMD - Market Capitalization to Book Value|ANVS (Annovis Bio, Inc.) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Grace Tx (GRCE)|Market Value to Book Value Ratio Firefly Neuroscience (AIFF)|Market Capitalization to Book Value anewmeds.com|NeuroSense Therapeutics Ltd. - Market Cap to Net Assets Ratio|Market Value to Book Value RVPH|MetaVia, Inc. - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value neuraxis.com NRXS|heliusmedical.com (HSDT) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio PASG|NEUP (Neuphoria Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Minerva (NERV)|Market Cap to Net Assets Ratio ATHA (Athira Pharma, Inc.)|Market Capitalization to Book Value addextherapeutics.com|Market Capitalization to Book Value Ratio ALZN (Alzamend Neuro)|CYCN - Market Cap to Net Assets Ratio|Protagenic - Market Capitalization to Book Value Ratio|KTTA - Market Capitalization to Book Value Ratio|cortigent.com (CRGT) - Market Value to Book Value Ratio|avenuetx.com - Market Value to Book Value|BCLI (BrainStorm Cell Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Chromocell Therapeutics Corp|Market Value to Book Value Ratio Eliem Therapeutics (ELYM)|intracellulartherapies.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio LBPH (Longboard Pharmaceuticals)|marinuspharma.com (MRNS) - Market-to-Book Ratio|NKGN: Market Cap to Net Assets Ratio|NRBO - Market Capitalization to Book Value Ratio|Sage Therapeutics, Inc (SAGE) - Market Value to Book Value Ratio|Synaptogenix, Inc - Market Value to Book Value|Market Value to Book Value Ratio Trevena, Inc.|Market-to-Book Ratio Vigil Neuro VIGL|Market Capitalization to Book Value Ratio WENA|Market Cap to Net Assets Ratio Cerevel Therapeutics Inc CERE